SCHEMBL5734812

SCHEMBL5734812

COC(=O)c1oc2ccc(OC)cc2c1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.72
SMN1; SMN2 Q16637 10/20 0.72
ALDH1A1 P00352 9/20 0.72
HPGD P15428 5/20 0.72
HSD17B10 Q99714 4/20 0.72
TP53 P04637 1/20 0.72
HTT P42858 1/20 0.72
NPC1 O15118 8/20 0.58
RAB9A P51151 8/20 0.58
NQO1 P15559 1/20 0.56
MAPT P10636 4/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 1/20 0.53
KMT2A Q03164 1/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10370973 0.88 KDM4E (0.59) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL5736633 0.86 KDM4E (0.60) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL27280522 0.86 KDM4E (0.74) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL719907 0.85 KDM4E (0.76) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL25963177 0.83 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL25338376 0.82 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL5736871 0.82 KDM4E (0.72) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL9434162 0.81 CASP3 (0.58) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL9433482 0.79 KDM4E (0.64) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL17179764 0.78 CFTR (0.47) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644364-A1 TETRAZOL BENZOFURANCARBOXAMIDES WITH PI3K ACTIVITY AS THERAPEUTIC AGENTS Warner-Lambert Company LLC (US) 2006-04-12 EP disclosed
US-20050020631-A1 3-Substituted benzofurans as therapeutic agents GOGLIOTTI ROCCO DEAN (US) 2005-01-27 US disclosed
WO-2004108709-A1 TETRAZOL BENZOFURANCARBOXAMIDES WITH P13K AKTIVITY AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 WO disclosed
US-5350748-A 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion WARNER-LAMBERT COMPANY (US) 1994-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020631-A1 3-Substituted benzofurans as therapeutic agents CYP4F11, BPTF, F3 KDM4E 2213/4885SMN1; SMN2 2260/4885ALDH1A1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.